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Abstract
Background: Metastatic renal cell carcinoma (RCC) is highly resistant to systemic chemotherapy. Unfortunately,
nearly all patients die of the metastatic and chemoresistant RCC. Recent studies have shown the atypical PKCζ is
an important regulator of tumorigenesis. However, the correlation between PKCζ expression and the clinical
outcome in RCC patients is unclear. We examined the level of PKCζ expression in human RCC.
Methods: PKCζ mRNA and protein expressions were examined by real-time polymerase chain reaction (PCR) and
immunohistochemistry (IHC) respectively in RCC tissues of 144 patients. Cellular cytotoxicity and proliferation were
assessed by MTT.
Results: PKCζ expression was significantly higher in normal than in cancerous tissues (P < 0.0001) by real-time PCR
and IHC. Similarly, PKCζ expression was down-regulated in four renal cancer cell lines compared to immortalized
benign renal tubular cells. Interestingly, an increase of PKCζ expression was associated with the elevated tumor
grade (P = 0.04), but no such association was found in TNM stage (P = 0.13). Tumors with higher PKCζ expression
were associated with tumor size (P = 0.048). Expression of higher PKCζ found a poor survival in patients with high
tumor grade. Down-regulation of PKCζ showed the significant chemoresistance in RCC cell lines. Inactivation of
PKCζ expression enhanced cellular resistance to cisplatin and paclitaxel, and proliferation in HK-2 cells by specific
PKCζ siRNA and inhibitor.
Conclusions: PKCζ expression was associated with tumorigenesis and chemoresistance in RCC.
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Background
The incidence of renal cell carcinoma (RCC) is increasing
worldwide [1]. RCC mainly arises from renal tubular
epithelia [2]. Surgical resection of the diseased tissue has
been considered the only curative treatment [3]. Meta-
static RCC (mRCC) is generally resistant to chemotherapy
and hormonal therapy and marginally sensitive to immu-
notherapy [4]. Although several promising therapeutic
strategies are now available for treating patients with
mRCC, nearly all patients die of the metastatic disease.
Research is ongoing to identify RCC-specific biomarkers
that can improve early diagnosis, surveillance of tumor
progression, and prediction of patient prognosis [5].
Markers such as growth factors, laminin, p53 mutations,
and others, have been recently examined [6-8]. Unfortu-
nately, none of these markers appear superior to the
traditional staging and grading systems. RCC is also char-
acterized by a high resistance to tumor cell apoptosis both
intrinsic and induced by radiation or systemic therapies,
including chemotherapy and immunotherapy [9-13]. How-
ever, the mechanisms of this resistance have not been
elucidated.
The PKC family includes at least 11 isoforms of closely
related serine/threonine protein kinases that regulate
important cellular processes, including proliferation, dif-
ferentiation, and apoptosis [14,15]. Members of this
family are classified into three subfamilies according to
their sequence homology and activating cofactor require-
ments [14]. The conventional PKCs (a, bI, bII, and g)a r e
activated by calcium (Ca
+2) and 1,2-diacyl-sn-glycerol,
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h) are activated by 1,2-diacyl-sn-glycerol, but are Ca
+2
independent. The atypical PKC isoforms (l, ζ and ι)a r e
both Ca
+2- and 1,2-diacyl-sn-glycerol independent [15].
Although PKC isoforms have overlapping substrate spe-
cificities in vitro [16], these kinases display distinct pat-
terns of tissue expression and intracellular localizations
that likely reflect unique isoform specific functions
[17,18].
PKC has been associated with tumor promotion, pro-
gression, invasion, and metastasis [16,19]. Accumulated
results have demonstrated PKCζ plays an important role
in human tumorigenesis of the colon, skin, prostate, lung,
and bladder [19-23]. Mustafi et al. suggested PKCζ might
inhibit cancer cell growth and enhance differentiation and
apoptosis [19]. Similarly, the down-regulation of PKCζ
may contribute to skin tumorigenesis by releasing con-
straints on Akt/PKB activity, proceeding during skin
tumor promotion and progression [24]. Inoue et al. also
suggested the PKCζ-mediated mammalian target of the
rapamycin/S6 kinase pathway plays an important role in
the transition of androgen-dependent to androgen-inde-
pendent prostate cancer cells [21]. In lung cancer, PKCζ
plays an important role in Par4 inhibition Akt activity and
Ras-induced tumorigenesis. Additionally, PKCζ was
involved in suppressing melanoma cell migration and
Rho-dependent prostate cancer cell proliferation and
apoptosis [24,25]. In aggregate, these data support the
hypothesis PKCζ may act as a novel tumor suppressor in
tumorigenesis. Conversely, recent studies have indicated
PKCζ played an oncogenic role to promote tumorgenesis
and inhibit apoptosis in breast cancer, head and neck
cancer [26,27].
The expression profile of PKCζ in the progression of
renal tumorigenesis has not been previously studied. To
address this question, we explored the role of PKCζ
expression in human RCC.
Methods
Chemicals and reagents
Anti-PKCζ and anti-a-tubulin antibodies were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA) and
Oncogene Science (Cambridge, MA), respectively. Protein
kinase Cζ pseudosubstrate inhibitor was obtained from
BioSource International Inc (Camarillo, CA). Specific
PKCζ siRNA was synthesized from Invitrogen (Invitrogen,
Carlsbad, CA). Cisplatin and paclitaxel were purchased
from Sigma Chemical Co. (St. Louis, MO, USA).
Cell culture
HK-2 is an immortalized cell line derived from human
proximal renal tubular cells. HK-2 cells were cultured in a
keratinocyte-serum free medium containing 5 ng/ml
recombinant epidermal growth factor and 40 μg/ml bovine
pituitary extract. The four utilized RCC cell lines were
769-P, 786-O and ACHN cells, maintained in RPMI-1640
medium, A498 cells were maintained in MEM medium.
These medium were supplemented with 10% fetal calf
serum (FCS) (Invitrogen), 100 μg/ml penicillin-streptomy-
cin, and 1% glutamine.
Cytotoxic assay
Cellular chemosensitivity to cisplatin and paclitaxel were
determined using a modified 3-(4,5-dimethylthiazo-2-yl)-
2,5-diphenyl tetrazolium (MTT, Sigma Chemical Co., ST.
Louis, MO) assay in vitro [28]. In brief, cells were treated
with anti-cancer drugs (each in 100 μl of culture medium)
simultaneously and incubated for 72 h. At 72 h, 50 μlo f
MTT (2 mg/ml) was added to each well and incubated for
2.5 h. Blue formazan crystals thus formed were pelleted to
the bottom of the well by centrifugation, separated from
the supernatant and dissolved in 150 μl of dimethylsulfox-
ymide. The optical density at 492 nm was determined by
absorbance spectrometry using a microplate reader
(MRX-2, Dynex Technologies, Inc., Chantilly, VA). Three
separate experiments with triplicate data were performed
to obtain mean cell viability.
PKCζ knock-down assay
The specific Stealth PKCζ small interfering RNA (siRNA)
was synthesized from Invitrogen for PKCζ knock-down.
PKCζ target siRNA sequence was 5’-GACAUGAACACA-
GAGGACUACCUUUU-3’. HK-2 cells (2 × 10
5) were pla-
ted into 10-cm plate overnight. Then cells were
transfected with 100 nM of PKCζ siRNA with lipofecta-
mine (Invitrogen) reagent for 24 h. Chemosensitivity of
HK-2 cells to cisplatin and paclitaxel was examined using
MTT assay after siRNA transfection.
Clinicopathological characteristics
This study had 144 patients with RCC, 98 males and 46
females with a mean age of 62.2 ± 12.2 years. Each pair
of tissues included a RCC tumor portion and normal-
looking renal cortical tissue from the same patient. These
specimens were obtained from nephrectomies carried out
at the National Taiwan University Hospital (NTUH).
Fuhrman’s nuclear grading system from I to IV was used
[29]. Tumors were staged according to the TNM system
and histologically classified according to WHO guidelines
[30]. The clinicopathological characteristics of the tumors
are summarized in Table 1. Approval from the Institu-
tional Review Boards of NTUH and Kaohsiung Medical
University were obtained and informed consent was
received from all participating patients.
Real-time PCR
Primers were synthesized to encompass a specific seg-
ment of the cDNA sequence of the PKCζ (forward
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reverse primer, 5’-TGCTGGATGCCTGCTCAA-3’), and
GADPH (forward primer, 5’-TCTCCTCTGACTTCAA-
CAGCGAC-3’; reverse primer, 5’-CCCTGTTGCTGT
AGCCAAATTC-3’)(Invitrogen). A master-mix of the
following reaction components was prepared with the
indicated final concentrations: 6.4 μlo fw a t e r ,1 . 2μlo f
MgCl2 (4 mM), 1 μl of forward primer (0.4 μM), 1 μlo f
reverse primer (0.4 μM) and 12.5 μl of LightCycler Fast
Start DNA Master SYBR Green I (PE Applied Biosys-
tems, Foster City, CA, USA). Nine microliters of the
master-mix was added to each well of a 96-well plate
and 1 μl containing 50 ng cDNA, was added as the PCR
template. The corresponding cDNA fragments were
denatured at 95°C for 15 sec and annealed at 60°C for
1 min. At the completion of 40-cycle, melting curve
analysis was performed to establish the specificity of the
amplicons produced. A ratio of specific mRNA/GADPH
(GADPH as a respective control) amplification was then
calculated (ΔCt vaule = CtPKCζ -C tGADPH), to correct for
any differences in efficiency. The fold changes were
calculated with the ΔΔCt method (the total ΔΔCt =f o l d
of cancerous/normal tissue gene level), using normal tis-
sue (for tissue samples) or HK-2 (for cell lines) as the
control.
Immunohistochemistry (IHC)
Immunostaining was performed as described previously
[19]. In brief, the sections were de-paraffinized in xylene
and rehydrated through graded alcohols, then boiled in
0.01 M citrate buffer (pH 6.0) for 10 min. Hydrogen per-
oxide, 0.3%, was added to block any endogenous peroxi-
dase activity. The sections were incubated with anti-
PKCζ antibody used at a 1:600 dilution at 4°C overnight.
Horseradish peroxidase (HRP) polymer conjugated was
used as a second antibody to avoid contaminating the
endogenous biotin or streptavidin (Zymed). After wash-
ing, the antigen-antibody complex was applied and
stained with diaminobenzidine (Golden Bridge, Mukilteo,
WA). Counterstaining was performed lightly with hema-
toxylin. The expression of PKCζ was evaluated according
to the ratio of positive cells per specimen and the staining
Table 1 Immunostaining expression of PKCζ in normal parenchymal and RCC tissues
Patients PKCζ protein expression (mean score ± SE)
Characteristic No. (%) Normal renal tubular cells RCC P value*
Total 144 (100) 161.1 ± 4.5 103.6 ± 4.5 < 0.0001
Sex
Male 98 (68) 158.5 ± 5.4 103.3 ± 5.5 < 0.0001
Female 46 (32) 166.5 ± 8.0 104.3 ± 7.9 < 0.0001
P value
† 0.41 0.91
Grade
I 19 (13) 166.8 ± 13.1 79.5 ± 10.6 < 0.0001
II 64 (45) 160.8 ± 6.7 101.7 ± 6.8 < 0.0001
III 32 (22) 168.1 ± 8.9 113.8 ± 9.1 < 0.0001
IV 15 (10.3) 166 ± 10.9 111.3 ± 15.1 0.009
ND 14 (9.7) 132.9 ± 18.1 109.3 ± 17.2 0.3
P for ANOVA
‡ 0.91 0.14
P for trend
¶ 0.79 0.04
Stage
Organ-confined (T1-2N0 M0) 95 (66) 159.1 ± 5.8 102.1 ± 5.6 < 0.0001
Locally advanced (T3-4 N0 M0) 31 (22) 160 ± 10.2 103.9 ± 8.5 < 0.0001
Metastatic (N1-2 or M1) 17 (11.3) 162.4 ± 11.3 115.3 ± 15.7 0.032
ND 1 (0.7) 200 50
P for ANOVA
‡ 0.97 0.67
P for trend
¶ 0.41 0.13
Histological type
Conventional 108 (75) 163.1 ± 4.9 98.1 ± 4.7 < 0.0001
Non-conventional 36 (25) 152.2 ± 11.2 115.6 ± 11.5 0.0082
P value
† 0.31 0.098
NOTE: PKCζ protein expression was examined by immunohistochemistry on a scale from 0 to 200 (percent positive cells × staining intensity). Non-conventional
type include papillary, chromophobe, sarcomatoid and collecting duct. Abbreviations: RCC, renal cell carcinoma; SE, standard error; TNM, tumor-node-metastasis;
ND, not determined. *: paired sample t test, †: Independent-sample t test for two groups, ‡: One-way ANOVA for three or more groups, ¶: Test for linear trend
based on the continuous variable
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procedure was used to generate an IHC score for each
tissue section. The ratio of positive cells per specimen
was evaluated quantitatively and scored from 0 ~ 100%
of the cells examined. Intensity was graded as follows: 0,
no signal; 1, weak; and 2, strong staining. A total score of
0 to 200 was finally calculated as the percentage of posi-
tive cells × staining intensity. The evaluation of immu-
n o s t a i n i n gw a sp e r f o r m e db yas i n g l ep a t h o l o g i s t( W .Y .
K), who was unaware of the fate of the patient or the tis-
sue site.
Western blotting analysis
Cell extracts (50 μg) were separated on 10% SDS-polyacry-
lamide gels and transferred to immobilon polyvinylidene
difluoride membranes (Millipore, Bedford, MA). After
blocking, the membranes were incubated with human spe-
cific anti-PKCζ (Santa Cruz Biotechnology) polyclonal
antibody at 4°C for 12 h, followed by the horseradish per-
oxidase-labeled second antibody, and developed with the
ECL system (Santa Cruz Biotechnology).
cDNA microarray
Total RNAs were extracted from 3 pairs of RCC and
adjacent normal kidney tissues from 3 patients. Thirty
micrograms RNA were reversely transcribed to cDNA by
SuperScript
® II reverse transcriptase in the presence of
aminoallyl-dUTPs (Invitrogen). The cDNA was labeled
by either Cy3 or Cy5 at the aminoallyl-dUTP sites using
a coupling reaction. Cye dye coupling efficiency was
determined by UV spectrophotometer to determine the
absorbance at 260 nm for DNA, 550 nm for Cy3 and
650 nm for Cy5. Labeled cDNA was hybridized to the oli-
gonucleotide probes of a TMSEC microarray (Taiwan
Genome Sciences, Taipei, Taiwan) at 50°C for overnight.
The microarray was washed, and the emission signals
were scanned using the GenePix 4000A Fluorescent
Scanner (Axon Instruments, South San Francisco, CA).
Each time point and condition was repeated typically on
at least three to five occasions. Microarrays were ana-
lyzed with the Scanalyze program, as written by Taiwan
Genome Sciences Inc, to determine the fluorescent inten-
sities of the Cy5 and Cy3 for each spot. The fluorescence
intensities were normalized by applying a scaling factor
so that the median fluorescence ratio of all spots with
detectable signals above background on each microarray
is 1.0. The data are then filtered so that only spots with
intensities that are three times greater than background
in either channel are included in the analysis. Only those
spots that displayed a 2-fold or greater difference in
fluorescence intensities between the two dyes are used to
generate gene clusters. A list of ~3,000 genes with altered
expression (P < 0.001) was generated using these analyses
criteria.
Statistical analysis
The levels of PKCζ mRNA between the normal and
RCC tissues were compared by the paired t-test. Data
are presented as the mean ± standard error of the
means (SEM). Independent-sample t test, One-way
ANOVA and linear trend test were used to compare
protein expression determined by IHC analysis. Kaplan-
Meier method was used to estimate the probability of
overall survival. The log-rank test was performed to
examine the association of PKCζ with overall survival.
All tests were two-sided with P < 0.05 being statistically
significant.
Results
Down-regulation of PKCζ in renal cell carcinoma (RCC)
Three pairs of RCC and normal renal parenchymal tis-
sues from the same patients were analyzed using cDNA
microarray, showing PKCζ gene expression in the cancer-
ous tissues was 3-fold lower than in the normal tissues
(P < 0.0001, Figure 1A). PKCζ mRNA expression was
determined with real-time PCR using five pairs of tissues
including the three used in the cDNA microarray experi-
ment (Figure 1B). PKCζ mRNA levels were significantly
higher in normal than in cancerous tissues (Figure 1B).
Similarly, the expression of PKCζ protein was estimated
in eight pairs of tissues by Western blotting (Figure 1C
and 1D).
Immunohistochemical analysis of PKCζ expression in
paired tissues
The expression of PKCζ protein was estimated in 144
pairs of tissues by immunohistochemistry (IHC). Specific
staining of PKCζ was observed in the cytoplasm. The
PKCζ protein staining was strongly positive in normal
renal tubular cells (Figure 2A-a) but weakly positive in
most cancerous epithelia (Figure 2A-b). IHC expression
levels were further quantified on a scale from 0 to 200
(Figure 2B and Table 1). The normal renal tissues had
markedly elevated scores of 161.1 ± 4.5 compared to the
RCC tissues scores of 103.6 ± 4.5 (P < 0.001), as presented
in Table 1. Interestingly, it showed an increase of PKCζ
protein expression was associated with elevated tumor
grade (P = 0.04), but no such association was found in
TNM stage (P = 0.13) using linear trend test (Table 1).
However, as shown in Table 1, PKCζ protein levels in the
RCC tissues did not differ between genders, tumor grades,
TNM stages, or histological types (all Ps > 0.05). Based on
tumor size from AJCC TNM classification for renal cell
carcinoma, we found RCC patients with bigger tumor size
had higher intensity of PKCζ expression (P = 0.048)
(Table 2). Although there was no significant correlation
between PKCζ expression and invasive growth characteris-
tic (P = 0.67), but it showed an increased trend for PKCζ
expression in RCC (Table 1).
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We evaluate the relationship between tumor grade and
5-year survival in a population of patients with RCC. As
s h o w ni nF i g u r e3 A ,t h et u m o rg r a d eI I Iw a ss i g n i f i -
cantly associated with poor outcome than grade I (P =
0.032) and II (P = 0.016) on 5-year survival, respectively.
Thus, higher expression of PKCζ was associated with
short survival time in RCC patients with higher tumor
grade. However, grade IV showed no significant 5-year
survival between grade I and grade II. The ratio of
PKCζ expression (cancer/normal ratio) was PKCζ score
of cancer compared with normal tissue from the same
patient. The median value of all RCC patients was 0.54.
Interestingly, we found the PKCζ ratio > 0.54 had signif-
icantly poor survival than ratio ≤ 0.54 on 5-year survival
in RCC (P = 0.042) (Figure 3B).
Down-regulation of PKCζ showed the higher
chemoresistance in RCC cell lines
PKCζ protein levels were significantly reduced in the four
RCC cell lines compared to HK-2 the benign immorta-
lized cell line by Western blotting (Figure 4A and 4B),
respectively. Similarly, PKCζ gene levels were decreased
in these RCC cell lines as estimated (data not shown).
We identified the molecular role of PKCζ in RCC cells.
The higher expression of PKCζ in HK-2 was with higher
sensitivity to cisplatin and paclitaxel than in the 786-O
and ACHN cell lines, respectively (Figure 4C and 4D).
Inactivation of PKCζ expression enhanced cellular
chemoresistance and proliferation
Knockdown of PKCζ expression in HK-2 by specific PKCζ
siRNA (Figure 5A and 5B), indicated down-regulated
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Figure 1 Down-regulation of PKCζ in RCC tissues. (A) Expression of PKCζ mRNA in 3 pairs of RCC and adjacent normal kidney tissues from 3
patients by cDNA microarray analysis. Fold change compared with normal kidney tissues. Paired sample t test was used to compare PKCζ
expression in the normal and RCC tissues (*P < 0.001). (B) Real-time PCR analysis of PKCζ in 5 pairs of RCC (T) and adjacent normal kidney
tissues (N) from 5 patients. (C) Expression of PKCζ protein in 8 pairs of normal and RCC tissues by Western blotting analysis. b-actin was used as
an internal control (D) The ration of protein intensity of PKC ζ/b-actin from Figure 1(C) was examined by densitometer analysis. Paired sample t
test was used to compare PKCζ expression in the normal and RCC tissues (*P < 0.05).
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cisplatin at the concentrations of 1, 3 and 10 μM, respec-
tively (P*<0 . 0 5 ,P** < 0.005 and P*** < 0.001) (Figure 5C).
Chemosensivity of HK-2-C (IC50 =2 . 0 5μM) and HK-2-
siRNA (IC50 =4 . 0 2μM) cells to cisplatin were examined
by MTT assay. The IC50 value was a near 2-fold increase
in HK-2-siRNA compared to HK-2-C. Similar results, che-
mosensivity of HK-2-C (IC50 = 0.09 μM) and HK-2-siRNA
(IC50 =0 . 1 7μM) cells to paclitaxel were examined by
MTT assay (Figure 5C). The IC50 value was a near 2-fold
increase in HK-2-siRNA compared to HK-2-C. Herein,
knockdown of PKCζ expression enhanced HK-2 cells the
resistance to paclitaxel at the concentrations of 0.1 and 3
μM, respectively (P* < 0.05 and P** < 0.005). Cell perme-
able protein kinase Cζ pseudosubstrate inhibitor was used
to inhibit the PKCζ activity of HK-2 cells. Interestingly, we
also found inactivation of PKCζ by specific inhibitor of
0.16 μMP K C ζ pseudosubstrate could promote signifi-
cantly cell growth in HK-2 cells (P < 0.05) (Figure 5D).
Discussion
PKCζ mRNA levels were down-regulated in human renal
cancerous tissues compared with their normal tissues, as
assessed by cDNA microarray analysis. Additional experi-
mental results confirmed both PKCζ protein and mRNA
levels were reduced in RCC tissues and cell lines, suggest-
ing PKCζ may serve as a biomarker for renal tumorigen-
esis. Interestingly, we found an increase of PKCζ protein
expression was associated with elevated tumor grade, but
no such association was found in TNM stage using linear
trend test. However, since the PKCζ expression level did
not differ between the varied genders, tumor grades, TNM
stages or histological types of RCC. We also found PKCζ
was involved in cell growth and chemoresistance of RCC
100X
a b
c d
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100X
a b
c d
e f
Normal RCC (A) (B)
Figure 2 Down-regulation of PKCζ in human conventional RCC tissues by Immunohistochemical staining. (A) Tissue sections of normal
parenchymal tissues (a, c) or RCC (b, d) were from the same patient. The polyclonal anti-PKCζ antibody was used to stain paraffin sections (a, b). The
negative control omitted the primary antibody (c, d). The brain tissue was used as a positive control for PKCζ expression (e). The tumor grade and
stage in (b) and (d): grade I and TNM stage T2N0M0. Original magnification, × 100. (B) Representative immunohistochemical staining of PKCζ
expression in normal parenchymal and RCC tissues. (a) and (b), negative staining (0+); (c) and (d), weakly positive staining (1+); (e) and (f), strongly
positive staining (2+), The tumor grade and stage in (b): grade I and TNM stage T1N0M0, in (d): grade II and TNM stage T1bN0M0 and (f): grade IV and
TNM stage T3aN1M1 (100 × magnification).
Table 2 Intensity of PKCζ expression was associated with
tumor size in RCC
Characteristics Intensity of PKCζ (N%)
a
Tumor size 0 1 2 c
2* P value
≤4 cm 0 42 17 9.57 0.048
(0) (48.8) (34.7)
4-7 cm 2 25 13
(100) (29.1) (26.5)
> 7 cm 0 19 19
(0) (22.1) (38.8)
a: patient numbers% (N%)
*: the association of PKCζ intensity with tumor size was analyzed by Chi-
Square test
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role in the tuomrigenesis andc h e m o r e s i s t a n c eo fR C C .
The phenomena might indicate expression of PKCζ down-
regulation could promote at early stage of RCC progres-
s i o n .T h e r e f o r e ,i tw a sn o ts urprising that expression of
PKCζ down-regulation in most cancerous compared with
normal at the same section.
Recent studies have suggested PKCζ might inhibit can-
cer cell growth, and enhance differentiation and apoptosis
[19,32]. Loss of this growth regulation is a characteristic
feature of malignant transformation [33]. Interestingly,
Wali et al. previously demonstrated that PKCζ was down-
regulated in azoxymethane-induced colonic carcinogenesis
[32]. They also found three structurally unrelated agents
inhibited azoxymethane tumorigenesis and concomitantly
prevented PKC-ζ down-regulation in these tumors.
Recently, Mustafi et al. have similar finding that PKCζ was
up-regulated expression during normal colonocyte
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Figure 3 The prognostic survival of PKCζ in RCC. (A) High tumor grade was associated with short survival time in RCC patients. Tumor grade III
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Page 7 of 11maturation, and loss of expression in colonic tumorigen-
e s i s ,a sw e l la sP K C ζ preservation by chemopreventive
agents. Thus they suggest that PKCζ may inhibit cancer
cell growth and enhance differentiation and apoptosis
[19]. We have searched the public domain from of NCBI
GEO profiles for analysis of the PKCζ RNA level in
human RCC microarray. Similarly, there two data profiles
were with the same as our experimental conditions in our
study demonstrated PKCζ expression was significantly
lower in RCC tissues than that in normal tissues.
(GDS2880/202178_at/PRKCZ/Homo sapiens and
GDS505/202178_at/PRKCZ/Homo sapiens). Herein, the
present study showed that PKCζ expression was signifi-
cantly down-regulation in RCC tissues and cell lines, and
inactivation of PKCζ could promote the cell growth in
HK-2 cell line. Based on these findings, we speculated that
PKCζ mediated interactions between integrins and extra-
cellular matrix that participated in cell-cell and cell-base-
ment membrane signaling. Because PKCζ played a critical
role in tight junction biogenesis in other cells [33], down-
regulation of this atypical isoform in renal tumorigenesis
might abrogate normal growth inhibition mediated by
cell-cell contact. Therefore, down-regulation of PKCζ in
renal tumorigenesis might abrogate normal growth inhibi-
tion mediated by cell-cell contact. These results indicate
PKCζ may be associated with renal tubular tumorgenesis.
In aggregate, these data support the hypothesis PKCζ may
act as a novel tumor suppressor in renal tumorigenesis.
However, some studies have shown PKCζ up-regulation
and activation in tumorigenesis [34-36], conflicting with
the results in this study, but not all reports have thor-
oughly confirmed this observation in human RCC [37].
Herein, our results revealed down-regulation of PKCζ may
be an important phenomenon in the tumor progression
from normal to precancer cells or in situ early cancer sta-
tus. We hypothesized that known-down or inhibition of
PKCζ expression in the precancer lesions may therefore
abolish the growth suppressive function of this protein
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Page 9 of 11and enable rapid proliferation and promoting early cancer
development. However, up-regulation of PKCζ expression
from a precancer lesion to cancer may imply a differing
promotion rather than suppressive function of PKCζ in
this stage of disease progression.
An increase of tumor grade was known to be asso-
ciated with poor survival. Although, the level of PKCζ
gene expression was lower in cancer tissue compared
with that in paired normal tissue, an increase of PKCζ
protein expression in cancer tissues was associated with
higher tumor grade using linear trend test (Table 1).
However, no such association was found in paired nor-
mal tissue samples and those with different TNM cancer
stages. These data could partially explain why the high
expression of PKCζ was associated with poorer clinical
prognosis with ratio (cancer/normal) more 0.54 had sig-
nificantly poor survival.
We also showed the higher intensity of PKCζ expres-
sion in RCC was associated with greater tumor size
(Table 2). The tumor size at a given stage was regulated
and balanced by specific interactions of multiple factors,
for example cellular proliferation, apoptosis and angio-
genesis. Previous studies ha v es h o w nt h ei n d u c t i o no f
hypoxic stress, altered microenvironmental pH and
growth factors and removed ECM contacts become pro-
minent with the expansion of tumor size [38]. Previously,
Datta et al. have demonstrated that PKCζ down-regulated
the total mRNA level of FIH-1 and thereby helped HIF-
2/HIF-1a to be activated in RCC cell lines [37]. Due to
HIF involved in various physiological processes of renal
tuomrigenesis during hypoxia, so we predicted PKCζ
might play a protective role in the inner of tumor mass
from hypoxia-mediated damage in RCC. Whether PKCζ
expression played a contributo r yr o l eo rr e f l e c t e dac o n -
sequence of increased RCC tumor mass, however still
remained to be further studied.
Metastatic RCC is usually with highly resistant to sys-
temic chemotherapy, and nearly all patients die of this
metastatic disease [4]. However, the mechanisms of
RCC chemoresistance are not well-known studied now.
The involvement of PKC pathways in resistance to che-
motherapeutic treatments has been studied for quite a
long time. The two mechanisms that mainly account for
the participation of PKCs in chemotherapeutic resis-
tance are: (a) the modulation of multi-drug transporters,
and (b) the regulation of apoptosis [39]. Further studies
have revealed PKC activation is not always associated
with resistance, but can also increase sensitivity to che-
motherapy. For example, while expression of PKCa and
PKCg increases the resistance of human uterine sarcoma
cells to paclitaxel, elevated expression of PKCι/l, leads
to reversal of the resistance [40]. Likewise, PKCa over-
expression has been associated with increased multi-
drug resistance expression. However, in the MDA-MB-
231 breast cancer cells, expression of PKCa confers sen-
sitivity to retinoic acid treatment [41]. Interestingly,
PKCδ also shows disparate effects in the apoptotic
responses to anti-cancer drugs. It seems to act as an
anti-apoptotic mediator. Therefore, these findings
underlie the relevance of isoform specificity rather than
total PKC activity, in the cellular responses to anticancer
drugs [42]. Our study also found down-regulation of
PKCζ showed the higher chemoresistance in RCC cell
lines. PKCζ down-regulation may be associated with
chemoresistance in RCC. However, further studies are
necessary for elucidating the chemoresistant mechanism
of PKCζ of RCC.
Conclusions
PKCζ expression was shown to be significantly down-
regulated in RCC tissues and cell lines, and it may be
associated with tumorigenesis and chemoresistance in
RCC. To our knowledge, this is the first study showing
an association of PKCζ expression levels and renal tubu-
lar tumorigenesis. These findings suggest PKCζ may be
a potential biomarker for renal tumorigenesis. PKCζ
may become the focus of a new strategy of targeted
therapy for renal cancer by restoring the PKCζ expres-
sion in precancerous or cancerous cells. However, the
uncovering mechanisms remained to be further studied.
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